Antithrombotic strategies and DOAC dosing following left atrial appendage occlusion: a network meta-analysis
European Heart Journal - Cardiovascular Pharmacotherapy · 02.02.2026 · 12 (1) · 38-51
DOI: 10.1093/ehjcvp/pvaf078 ↗Kurz gefasst
Systematische Übersicht in der Zeitschrift European Heart Journal - Cardiovascular Pharmacotherapy, online erschienen am 25.11.2025. Verfasst von Athanasios Samaras und 11 weiteren Autor:innen. Beteiligte Einrichtung: School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece. Hauptthemen laut MEDLINE: Atrial Appendage, Atrial Fibrillation, Thromboembolism, Stroke. Die Arbeit wurde bisher 17-mal zitiert (Crossref) und nennt 47 Literaturangaben. Der Volltext ist frei zugänglich (Open Access, CC BY 4.0).
Abstract (Originalsprache)
Aims
The optimal short-term antithrombotic strategy following left atrial appendage occlusion (LAAO) remains uncertain, with the need to balance thromboembolic prevention and bleeding risk presenting a critical challenge. Recent evidence suggests that direct oral anticoagulants (DOACs) may provide a favourable safety–efficacy profile, with low-dose regimens showing potential benefits during the device endothelialization period. This network meta-analysis (NMA) aimed to compare the efficacy and safety of various antithrombotic strategies, including DOAC dosing, following LAAO. Methods and results A systematic review and NMA were conducted following Cochrane and PRISMA guidelines. Eligible studies included randomized controlled trials (RCT) and observational studies comparing at least two antithrombotic regimens in patients with non-valvular atrial fibrillation undergoing percutaneous LAAO. Primary outcomes were major bleeding and thromboembolism. Secondary outcomes included device-related thrombosis (DRT) and all-cause mortality. Pairwise and network meta-analyses were performed using a random-effects model. A total of 52 studies (49 observational and 3 RCTs) involving 69 751 patients were included. DOACs were consistently associated with significantly lower rates of major bleeding and all-cause mortality than other antithrombotic regimens. Low-dose DOACs showed a potential advantage over standard-dose DOACs in reducing major bleeding risk (odds ratio 0.45, 95% confidence interval: 0.22–0.92). For thromboembolism and DRT, standard-dose DOAC significantly reduced risk compared with single antiplatelet therapy (SAPT) but not with dual antiplatelet therapy (DAPT), whereas low-dose DOAC significantly reduced both outcomes compared with SAPT, DAPT, and vitamin K antagonists plus SAPT. In ranking analysis, DOACs emerged as the most effective and safest antithrombotic strategy, with low-dose DOACs demonstrating further safety benefits in bleeding outcomes.
Conclusion
DOACs provide a superior safety–efficacy profile compared with other antithrombotic strategies following LAAO, significantly reducing the risks of major bleeding, thromboembolic events, and mortality. While low-dose DOACs may offer additional bleeding risk reduction without compromising efficacy, further research is warranted to confirm their role in clinical practice.
Schlagwörter
MeSH-Schlagwörter (MEDLINE)
Stichwörter der Autor:innen
Substanzen
Autor:innen und Institutionen
- School of Medicine, Faculty of Health Sciences, Aristotle University of Thessaloniki, 54124 Thessaloniki, Greece.
- Second Department of Cardiology, General Hospital 'Hippokration', 54642 Thessaloniki, Greece.
- Department of Cardiology, Heart Center, University of Cologne, 50937 Cologne, Germany.
- First Department of Cardiology, AHEPA University Hospital of Thessaloniki, 54636 Thessaloniki, Greece.
- Department of Cardiology, Aarhus University Hospital, 8200 Aarhus, Denmark.
- Department of Cardiology, Institut Cardiovascular, IDIBAPS, Hospital Clinic of Barcelona, 08036 Barcelona, Spain.
ORCID-Profile: Athanasios Samaras, Paschalis Karakasis, George Giannakoulas, Martin Bergmann, Apostolos Tzikas
Zitieren
APA
Samaras, A., Karakasis, P., Feidakis, A., Giannakoulas, G., Fragakis, N., Nielsen-Kudsk, J. E., Freixa, X., Nair, D. G., Freeman, J. V., Bergmann, M., Landmesser, U., & Tzikas, A. (2026). Antithrombotic strategies and DOAC dosing following left atrial appendage occlusion: a network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy, 12(1), 38-51. https://doi.org/10.1093/ehjcvp/pvaf078
Vancouver
Samaras A, Karakasis P, Feidakis A, Giannakoulas G, Fragakis N, Nielsen-Kudsk JE, et al. Antithrombotic strategies and DOAC dosing following left atrial appendage occlusion: a network meta-analysis. European Heart Journal - Cardiovascular Pharmacotherapy. 2026;12(1):38-51. doi:10.1093/ehjcvp/pvaf078
BibTeX
@article{Samaras2026,
author = {Samaras, Athanasios and Karakasis, Paschalis and Feidakis, Athanasios and Giannakoulas, George and Fragakis, Nikolaos and Nielsen-Kudsk, Jens-Erik and Freixa, Xavier and Nair, Devi G and Freeman, James V and Bergmann, Martin and Landmesser, Ulf and Tzikas, Apostolos},
title = {Antithrombotic strategies and DOAC dosing following left atrial appendage occlusion: a network meta-analysis},
journal = {European Heart Journal - Cardiovascular Pharmacotherapy},
year = {2026},
volume = {12},
number = {1},
pages = {38--51},
doi = {10.1093/ehjcvp/pvaf078}
}
EUVIMED